Department of General Surgery/Shanghai Clinical Nutrition Research Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Medicine, Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan, Shandong, China; Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
Int Immunopharmacol. 2023 Nov;124(Pt B):111001. doi: 10.1016/j.intimp.2023.111001. Epub 2023 Oct 5.
Cachexia, marked by muscle atrophy, poses substantial challenges for prevention and treatment. This study delves into the unclear role of butyrate, a gut microbiota metabolite, in cachexia by examining gut microbiota and short-chain fatty acid (SCFA) profiles in human and mouse fecal samples.
We analyzed cachexia-associated gut microbiota and SCFA profiles using 16S rRNA sequencing and metabolomic techniques. Mouse cachexia models were developed with C26 cells, and LPS was used to induce muscle cell atrophy in C2C12 cells. We evaluated butyrate's in vivo effects on intestinal health, muscle preservation, inflammation, and macrophage activity. In vitro studies focused on butyrate's influence on macrophage polarization and the subsequent effects on muscle cells.
Both cachexia patients and mice exhibited gut microbiota imbalances, irregular butyrate concentrations, and a decline in butyrate-producing bacteria. In vivo tests showed that butyrate counteract cachexia-induced muscle atrophy by adjusting the Akt/mTOR/Foxo3a and Fbox32/Trim63 pathways. These butyrate also bolstered intestinal barrier integrity, minimized endotoxin migration, and mitigated oxidative stress. Furthermore, butyrate curtailed inflammation and macrophage penetration in muscles. In vitro experimental results demonstrate that butyrate inhibit macrophage polarization towards the M1 phenotype and promote polarization towards the M2 phenotype. Both M1 and M2 macrophages influence the aforementioned pathways and oxidative stress, participating in the regulation of muscle cell atrophy.
Our study delineates the intricate interplay between gut microbiota dysbiosis, butyrate fluctuations, and cachexia progression. Butyrate not only reinforces the intestinal barrier but also orchestrates macrophage polarization, mitigating muscle atrophy and averting cachexia-induced muscle deterioration. Concurrently, the M1 and M2 macrophages play pivotal roles in modulating skeletal muscle cell atrophy. This highlights the potential of utilizing the gut-derived metabolite butyrate as a promising therapeutic approach for addressing cachexia-related issues.
以肌肉萎缩为特征的恶病质对预防和治疗构成了重大挑战。本研究通过研究人和小鼠粪便样本中的肠道微生物群和短链脂肪酸(SCFA)谱,探讨了肠道微生物群代谢物丁酸盐在恶病质中的作用。
我们使用 16S rRNA 测序和代谢组学技术分析与恶病质相关的肠道微生物群和 SCFA 谱。使用 C26 细胞建立了恶病质小鼠模型,并用 LPS 诱导 C2C12 细胞肌萎缩。我们评估了丁酸盐对肠道健康、肌肉保护、炎症和巨噬细胞活性的体内作用。体外研究集中在丁酸盐对巨噬细胞极化的影响以及随后对肌肉细胞的影响。
恶病质患者和小鼠均表现出肠道微生物群失衡、丁酸盐浓度不规则以及产生丁酸盐的细菌减少。体内试验表明,丁酸盐通过调节 Akt/mTOR/Foxo3a 和 Fbox32/Trim63 途径来对抗恶病质引起的肌肉萎缩。这些丁酸盐还增强了肠道屏障的完整性,减少了内毒素迁移,并减轻了氧化应激。此外,丁酸盐还减少了肌肉中的炎症和巨噬细胞浸润。体外实验结果表明,丁酸盐抑制巨噬细胞向 M1 表型极化,并促进向 M2 表型极化。M1 和 M2 巨噬细胞均影响上述途径和氧化应激,参与调节肌肉细胞萎缩。
本研究描绘了肠道微生物群失调、丁酸盐波动和恶病质进展之间的复杂相互作用。丁酸盐不仅增强了肠道屏障,还协调了巨噬细胞极化,减轻了肌肉萎缩,避免了恶病质引起的肌肉恶化。同时,M1 和 M2 巨噬细胞在调节骨骼肌细胞萎缩中发挥着重要作用。这凸显了利用肠道衍生代谢物丁酸盐作为治疗恶病质相关问题的有前途的治疗方法的潜力。